DEVELOPING EUROPE & CIS

The main revenue contributor to our Developing Europe & CIS business is the Thrombosis portfolio, followed by the Anaesthetics portfolio which is anticipated to become a significant contributor in this region.

Key Countries

The Czech Republic
Poland
Romania
Russia
Slovakia

Contribution to Group revenue (%)

Revenue by segment (%)

Injectable anticoagulants across Developing Europe & CIS grew by 2% in value as measured in Euros for the period ended 31 December 2018

Source: December 2018 IQVIA

STATISTICS

Number of products launched:

Nil

(2018: Nil)

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:

0 – 2 years

Nil

3 – 5 years

Nil

Number of product recalls:

Nil

(2018: Nil)

Average staff turnover:

17,5%

(2018: 14,5%)

Number of work-related fatalities:

Nil

(2018: Nil)

Number of permanent employees:

Revenue	2019 R'million	2017 (CER) R'million	change %
Total	2 516	2 810	(10)
Regional Brands	365	438	(17)
Sterile Focus Brands	2 151	2 372	(9)
Anaesthetics Brands	283	411	(31)
Thrombosis Brands	1 868	1 961	(5)